Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 – 2015)

References

• Jenke-Kodama H, Sandmann A, Müller R, et al. Evolutionary implications of bacterial polyketide synthases. Mol Biol Evol. 2005;22:2027–2039.
   PubMed Web of Science ®Google Scholar
• Brinster S, Lamberet G, Staels B, et al. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature. 2009;458:83–86.
   PubMed Web of Science ®Google Scholar
• Yao J, Rock CO. How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics. J Biol Chem. 2015;290:5940–5946.
   PubMed Web of Science ®Google Scholar
• Parsons JB, Frank MW, Subramanian C, et al. Metabolic basis for the differential susceptibility of gram-positive pathogens to fatty acid synthesis inhibitors. Proc Natl Acad Sci USA. 2011;108:15378-83, S78/1-S78/10.
   Web of Science ®Google Scholar
• Balemans W, Lounis N, Gilissen R, et al. Essentiality of FASII pathway for Staphylococcus aureus. Nature. 2010;463:E3. discussion E4
   PubMed Web of Science ®Google Scholar
• Marrakchi H, Laneelle MA, Daffe M. Mycolic acids: structures, biosynthesis, and beyond. Chem Biol. 2014;21:67–85.
   PubMed Web of Science ®Google Scholar
• Kumar K, Chopra S. New drugs for methicillin-resistant Staphylococcus aureus: an update. J Antimicrob Chemother. 2013;68:1465–1470.
   PubMed Web of Science ®Google Scholar
• Okombo J, Chibale K. Antiplasmodial drug targets: a patent review (2000-2013). Expert Opin Ther Pat. 2016;26:107–130.
   PubMed Web of Science ®Google Scholar
• Wickramasinghe SR, Inglis KA, Urch JE, et al. Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis. Biochem J. 2006;393:447–457.
   PubMed Web of Science ®Google Scholar
• Joshi SD, Dixit SR, More UA, et al. Enoyl ACP reductase as effective target for the synthesized novel antitubercular drugs: a-state-of-the-Art. Mini-Reviews Med Chem. 2014;14:678–693.
   PubMed Web of Science ®Google Scholar
• Lu XY, Huang K, You QD. Enoyl acyl carrier protein reductase inhibitors: a patent review (2006-2010). Expert Opin Ther Pat. 2011;21:1007–1022.
   PubMed Web of Science ®Google Scholar
• Sivaraman S, Sullivan TJ, Johnson F, et al. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. J Med Chem. 2004;47:509–518.
   PubMed Web of Science ®Google Scholar
• Heath RJ, Li J, Roland GE, et al. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J Biol Chem. 2000;275:4654–4659.
   PubMed Web of Science ®Google Scholar
• Tipparaju SK, Joyasawal S, Forrester S, et al. Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase. Bioorg Med Chem Lett. 2008;18:3565–3569.
   PubMed Web of Science ®Google Scholar
• Mehboob S, Truong K, Santarsiero BD, et al. Structure of the Francisella tularensis enoyl-acyl carrier protein reductase (FabI) in complex with NAD plus and triclosan. Acta Crystallogr Sect F-Struct Biol Cryst Commun. 2010;66:1436–1440.
   PubMedGoogle Scholar
• Parikh SL, Xiao GP, Tonge PJ. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry. 2000;39:7645–7650.
   PubMed Web of Science ®Google Scholar
• McMurry LM, McDermott PF, Levy SB. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob Agents Chemother. 1999;43:711–713.
   PubMed Web of Science ®Google Scholar
• Surolia N, Surolia A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat Med. 2001;7:167–173.
   PubMed Web of Science ®Google Scholar
• Vaughan AM, O’Neill MT, Tarun AS, et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol. 2009;11:506–520.
   PubMed Web of Science ®Google Scholar
• Dann AB, Hontela A. Triclosan: environmental exposure, toxicity and mechanisms of action. J Appl Toxicol. 2011;31:285–311.
   PubMed Web of Science ®Google Scholar
• Suller MTE, Russell AD. Triclosan and antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother. 2000;46:11–18.
   PubMed Web of Science ®Google Scholar
• Sullivan TJ, Truglio JJ, Boyne ME, et al. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem Biol. 2006;1:43–53.
   PubMed Web of Science ®Google Scholar
• Freundlich JS, Wang F, Vilcheze C, et al. Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. Chemmedchem. 2009;4:241–248.
   PubMed Web of Science ®Google Scholar
• Luckner SR, Liu NN, Ende CWA, et al. A slow, tight binding inhibitor of InhA, the Enoyl-Acyl carrier protein reductase from Mycobacterium tuberculosis. J Biol Chem. 2010;285:14330–14337.
   PubMed Web of Science ®Google Scholar
• Holas O, Ondrejcek P, Dolezal M. Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade. J Enzyme Inhib Med Chem. 2015;30:629–648.
   PubMed Web of Science ®Google Scholar
• Keum GC, Kim EG, Bae AN, et al. Preparation of triclosan derivatives as antibiotics. KR2011058557A. 2011.
   Google Scholar
• Lellouche JP, Makarovsky I, Boguslavsky Y, et al. Triclosan derivatives and nanoparticles comprising same. US20120183619A1. 2012.
   Google Scholar
• Makarovsky I, Boguslavsky Y, Alesker M, et al. Novel triclosan-bound hybrid-silica nanoparticles and their enhanced antimicrobial properties. Adv Funct Mater. 2011;21:4295–4304.
   Web of Science ®Google Scholar
• Gerusz V, Faivre F, Oxoby M, et al. Preparation of hydroxyphenyl compound as antibacterial agent for treating microbial infections. WO2011026529A1. 2011.
   Google Scholar
• Escaich S, Prouvensier L, Saccomani M, et al. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011;55:4692–4697.
   PubMed Web of Science ®Google Scholar
• Mouze-Soulama C, Gerusz V, Denis A. Novel drug combination for treating microbial infections. WO2015028104A1. 2015.
   Google Scholar
• Gerusz V, Mouze C, Van Dycke F, et al. Antibacterial nanosuspension comprising 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide. WO2015028637A1. 2015.
   Google Scholar
• Gerusz V, Denis A, Faivre F, et al. From triclosan toward the clinic: discovery of nonbiocidal, potent fabi inhibitors for the treatment of resistant bacteria. J Med Chem. 2012;55:9914–9928.
   PubMed Web of Science ®Google Scholar
• Gerusz V, Escaich S, Oxoby M, et al. Preparation of acylpiperazinones as inhibitors of bacterial FabI enzyme. WO2011048153A1. 2011.
   Google Scholar
• Shin KJ, Roh EJ, Chung MK, et al. Preparation of 3-phenoxy-4-pyrone, 3-phenoxy-4-pyridone or 4-pyridone derivatives as FabI (enoyl-ACP reductase) inhibitors. WO2011014008A2. 2011.
   Google Scholar
• Miller WH, Seefeld MA, Newlander KA, et al. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J Med Chem. 2002;45:3246–3256.
   PubMed Web of Science ®Google Scholar
• Seefeld MA, Miller WH, Newlander KA, et al. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J Med Chem. 2003;46:1627–1635.
   PubMed Web of Science ®Google Scholar
• Miller WH, Newlander KA, Seefeld MA, et al. Preparation of N-[indolyl(or indazolyl)methyl] benzamides as Fab I inhibitors. WO2001026652A1. 2001.
   Google Scholar
• Berman J, Sampson P, Pauls HW, et al. Preparation of heterocyclic compounds as antibacterial agents. WO2004052890A1. 2004.
   Google Scholar
• Berman JM, Schmid MB, Mendlein JD, et al. Compositions comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocycle FabI inhibitors. WO2004082586A2 2004.
   Google Scholar
• Berman JM, Schmid MB, Mendlein JD, et al. Compositions comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocycle FabI inhibitors. US20060142265A1. 2006.
   Google Scholar
• Pauls H, Berman JM. Preparation of 3-heterocyclylacrylamide derivatives as FaBI protein inhibitors for treating bacterial infection. WO2007067416A2. 2007.
   Google Scholar
• Pauls HW, Ramnauth J, Sampson P, et al. Preparation of heterocycle substituted acrylamides as FabI inhibitors. WO2008009122A1. 2008.
   Google Scholar
• Edwards A, Dharamsi A, Houston S, et al. S. aureus enoyl-[acyl carrier protein] reductase gene FabI, its recombinant expression and protein crystal structure, and use thereof as a target for antibacterial drug design and screening. WO2005005469A2. 2005.
   Google Scholar
• Berman JM, Schmid MB, Awrey DE, et al. Cloning and physical characterization of FabI polypeptide from Francisella tularensis and its use as a antimicrobial target. WO2006028561A2. 2006.
   Google Scholar
• Dharamsi AI, Domagala M, Clarke T. Biochemical and biophysical characteristics, including crystal structure, of enoyl-[acyl carrier protein] reductase from Helicobacter pylori and its use for molecular modeling and drug design. WO2007093848A2. 2007.
   Google Scholar
• Rangarajan R, Kumar R, Prabhakar BV, et al. Preparation of heterocycle-substituted N-methyl acrylamides as inhibitors of fatty acid biosynthesis for bacterial infections. WO2013042035A1. 2013.
   Google Scholar
• Gerusz V, Escaich S, Oxoby M, et al. Preparation of novel heterocyclic acrylamides and their use as pharmaceuticals. WO2011061214A1. 2011.
   Google Scholar
• Takhi M, Sreenivas K, Reddy CK, et al. Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors. Eur J Med Chem. 2014;84:382–394.
   PubMed Web of Science ®Google Scholar
• Guillemont JEG, Lancois DFA, Motte MMS, et al. Preparation of piperidinyl-substituted 3,4-dihydro-1H-[1,8]naphthyridinones useful as antibacterial agents. WO2013021052A1. 2013.
   Google Scholar
• Guillemont JEG, Lancois DFA, Motte MMS, et al. Preparation of homopiperidinyl-substituted 3,4-dihydro-1H-[1,8]naphthyridinones useful as antibacterial agents. WO2013021051A1. 2013.
   Google Scholar
• Guillemont JEG, Lancois DFA, Motte MMS, et al. Preparation of cyclopenta[c]pyrrole-substituted 3,4-dihydro-1H-[1,8]naphthyridinones useful as antibacterial agents. WO2013021054A1. 2013.
   Google Scholar
• Guillemont JEG, Lancois DFA, Motte MMS, et al. Preparation of tetrahydroazepine derivatives for use as antibacterial agents. WO2014023815A1. 2014.
   Google Scholar
• Guillemont JEG, Lancois DFA, Motte MMS, et al. Preparation of hexahydrocyclopentapyrrole derivatives and analogs for use as antibacterial agents. WO2014023814A1. 2014.
   Google Scholar
• Takhi M, Hosahalli S, Panigrahi SK, et al. Preparation of pyridine derivatives as FabI inhibitors. WO2013080222A1. 2013.
   Google Scholar
• Takhi M, Hosahalli S, Panigrahi SK, et al. Tetrahydropyridine derivatives as FabI inhibitors and their preparation, pharmaceutical compositions and use in the treatment of bacterial infection. US20140275019A1. 2014.
   Google Scholar
• Takhi M, Hosahalli S, Panigrahi SK. Fused pyridine derivatives as antibacterial agents and their preparation. WO2014072930A2. 2014.
   Google Scholar
• Takhi M, Hosahalli S, Panigrahi SK. Alkylidene substituted heterocyclyl derivatives as anti-bacterial agents. WO2015071780A1. 2015.
   Google Scholar
• Johnson M, Christie S, Ghosh A, et al. Enoyl reductase inhibitors with antibacterial activity. WO2014043246A1. 2014.
   Google Scholar
• Mehboob S, Song JH, Hevener KE, et al. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI). Bioorg Med Chem Lett. 2015;25:1292–1296.
   PubMed Web of Science ®Google Scholar
• Mehboob S, Hevener KE, Truong K, et al. Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis Enoyl reductase (FabI) inhibitors. J Med Chem. 2012;55:5933–5941.
   PubMed Web of Science ®Google Scholar
• Ratan Kale R, Madhavapeddi P, Raghunath Ghorpade S, et al. Preparation of pyrimidine isoxazole amide compounds for treating tuberculosis. WO2015181799A1. 2015.
   Google Scholar
• Castro Pichel J, Fernandez Menendez R, Fernandez Velando EP, et al. Preparation of 3-aminopyrazole derivatives for treatment of tuberculosis. WO2012049161A1. 2012.
   Google Scholar
• Ballell Pages L, Castro Pichel J, Fernandez Menendez R, et al. Preparation of N-(1H-pyrazol-3-yl)-1,3,4-thiadiazol-2-amine derivatives for the treatment of tuberculosis. WO2010118852A1. 2010.
   Google Scholar
• Shirude PS, Madhavapeddi P, Naik M, et al. Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. J Med Chem. 2013;56:8533–8542.
   PubMed Web of Science ®Google Scholar
• Kondreddi RR, Manjunatha UH, Ngai LM, et al. Preparation of pyridone derivatives useful in the treatment of tuberculosis. WO2014093606A1. 2014.
   Google Scholar
• Ng PS, Manjunatha UH, Rao SPS, et al. Structure activity relationships of 4-hydroxy-2-pyridones: a novel class of antituberculosis agents. Eur J Med Chem. 2015;106:144–156.
   PubMed Web of Science ®Google Scholar
• Manjunatha UH, Rao SPS, Kondreddi RR, et al. Direct inhibitors of InhA are active against Mycobacterium tuberculosis. Sci Transl Med. 2015;7:10.
   Web of Science ®Google Scholar
• Fehr M, Pahlke G, Fritz J, et al. Alternariol acts as a topoisomerase poison, preferentially affecting the IIα isoform. Mol Nutr Food Res. 2009;53:441–451.
   PubMed Web of Science ®Google Scholar
• Dellafiora L, Dall’Asta C, Cruciani G, et al. Molecular modelling approach to evaluate poisoning of topoisomerase I by alternariol derivatives. Food Chem. 2015;189:93–101.
   PubMed Web of Science ®Google Scholar
• Kim WG, Kim N, Kwon YJ. Alternariol derivatives with antimicrobial activity. KR2014107993A. 2014.
   Google Scholar
• Kim WG, Kim N, Sohn MJ. Novel antibacterial compounds isolated from Penicillium sp. WO2013115619A2. 2013.
   Google Scholar
• Kim WG, Kim N, Son MJ. Antibacterial compounds from culture of Penicillium sp. KR2013090295A. 2013.
   Google Scholar
• Kim N, Sohn M-J, Koshino H, et al. Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375. Bioorg Med Chem Lett. 2014;24:83–86.
   PubMed Web of Science ®Google Scholar
• Kim N, Sohn MJ, Kim CJ, et al. Verrulactones A and B, new inhibitors of Staphylococcus aureus enoyl-ACP reductase produced by Penicillium verruculosum F375. Bioorg Med Chem Lett. 2012;22:2503–2506.
   PubMed Web of Science ®Google Scholar
• Kim N, Sohn M-J, Koshino H, et al. Verrulactones D and E with unprecedented skeletons, new inhibitors of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375. J Antibiot. 2016;69:114–118.
   PubMed Web of Science ®Google Scholar
• Pero RW, Posner H, Blois M, et al. Toxicity of metabolites produced by the Alternaria. Environ Health Perspect. 1973;4:87–94.
   PubMedGoogle Scholar
• Yu M, Kumar TRS, Nkrumah LJ, et al. The fatty acid biosynthesis enzyme fabi plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe. 2008;4:567–578.
   PubMed Web of Science ®Google Scholar
• Samuel BU, Hearn B, Mack D, et al. Delivery of antimicrobials into parasites. Proc Natl Acad Sci. 2003;100:14281–14286.
   PubMed Web of Science ®Google Scholar
• Muench SP, Stec J, Zhou Y, et al. Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides. Bioorg Med Chem Lett. 2013;23:3551–3555.
   PubMed Web of Science ®Google Scholar
• McLeod R, Muench SP, Rafferty JB, et al. Cloning and sequencing of Plasmodium falciparum Fab I (enoyl acyl carrier protein reductase) gene and method for inhibition of apicomplexan parasites. WO2002049576A2. 2002.
   Google Scholar
• Stec J, Vilcheze C, Lun S, et al. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase inha in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis. ChemMedChem. 2014;9:2528–2537.
   PubMed Web of Science ®Google Scholar
• Stec J, Fomovska A, Afanador GA, et al. Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in toxoplasma gondii. Chemmedchem. 2013;8:1138–1160.
   PubMed Web of Science ®Google Scholar
• Afanador GA, Muench SP, McPhillie M, et al. Discrimination of potent inhibitors of toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry. 2013;52:9155–9166.
   PubMed Web of Science ®Google Scholar
• Schrader FC, Glinca S, Sattler JM, et al. Novel type II fatty acid biosynthesis (FAS II) inhibitors as multistage antimalarial agents. Chemmedchem. 2013;8:442–461.
   PubMed Web of Science ®Google Scholar
• Surolia A, Banerjee T, Surolia N, et al. Benzothiophene carboxamide compounds, composition and applications thereof. US20120016014A1. 2012.
   Google Scholar
• Qidwai T, Khan F. Antimalarial drugs and drug targets specific to fatty acid metabolic pathway of Plasmodium falciparum. Chem Biol Drug Des. 2012;80:155–172.
   PubMed Web of Science ®Google Scholar
• Hafkin B, Kaplan N, Hunt TL. Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects. Future Microbiol. 2015;10:1805–1813.
   PubMed Web of Science ®Google Scholar
• Flamm RK, Rhomberg PR, Kaplan N, et al. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. Antimicrob Agents Chemother. 2015;59:2583–2587.
   PubMed Web of Science ®Google Scholar
• Kaplan N, Albert M, Awrey D, et al. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob Agents Chemother. 2012;56:5865–5874.
   PubMed Web of Science ®Google Scholar
• Narasimha Rao K, Lakshminarasimhan A, Joseph S, et al. AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei-Crystal structure, mode of action, and biological activity. Protein Sci. 2015;24:832–840.
   PubMed Web of Science ®Google Scholar
• Lei BF, Wei CJ, Tu SC. Action mechanism of antitubercular isoniazid - Activation Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor. J Biol Chem. 2000;275:2520–2526.
   PubMed Web of Science ®Google Scholar
• Ghattas MA, Mansour RA, Atatreh N, et al. Analysis of enoyl-acyl carrier protein reductase structure and interactions yields an efficient virtual screening approach and suggests a potential allosteric site. Chem Biol Drug Des. 2016;87:131–142.
   PubMed Web of Science ®Google Scholar
• Stierand K, Rarey M. Drawing the PDB: protein−ligand complexes in two dimensions. ACS Med Chem Lett. 2010;1:540–545.
   PubMed Web of Science ®Google Scholar